Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs ha...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Computational and Structural Biotechnology Journal |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037022004202 |
| _version_ | 1797978161876566016 |
|---|---|
| author | Weiwei Liu Chaoqun Liu Hui Wang Lijun Xu Jueyu Zhou Sihua Li Yu Cheng Rui Zhou Liang Zhao |
| author_facet | Weiwei Liu Chaoqun Liu Hui Wang Lijun Xu Jueyu Zhou Sihua Li Yu Cheng Rui Zhou Liang Zhao |
| author_sort | Weiwei Liu |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs have been successfully applied in the treatment of different cancers, the low effectiveness rate has dramatically restrained the clinical application of ICI treatment. N6-methyladenosine (m6A) modification is the most common RNA methylation. Recent studies have pointed out that m6A epigenetic modification could improve the efficacy of ICI blockade treatment. Here, we briefly summarize the relevant mechanisms of tumour immunity, the clinical application of ICIs, the resistance to ICI treatment in cancers, and the m6A epigenetic modification and how it regulates the response to ICI treatment. We attempted to provide a potential strategy for cancer therapy by targeting m6A modification combined with ICI blockade treatment. |
| first_indexed | 2024-04-11T05:18:32Z |
| format | Article |
| id | doaj.art-8c412b2c29f14aceb765cb671d7351f1 |
| institution | Directory Open Access Journal |
| issn | 2001-0370 |
| language | English |
| last_indexed | 2024-04-11T05:18:32Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Computational and Structural Biotechnology Journal |
| spelling | doaj.art-8c412b2c29f14aceb765cb671d7351f12022-12-24T04:54:27ZengElsevierComputational and Structural Biotechnology Journal2001-03702022-01-012051505161Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapyWeiwei Liu0Chaoqun Liu1Hui Wang2Lijun Xu3Jueyu Zhou4Sihua Li5Yu Cheng6Rui Zhou7Liang Zhao8Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Pathology & Guangdong Province Key Laboratory of Molecular Tumour Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, ChinaDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Pathology & Guangdong Province Key Laboratory of Molecular Tumour Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, ChinaDepartment of Medical Oncology, Affiliated Tumour Hospital of Guangzhou Medical University, Guangzhou, ChinaDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Pathology & Guangdong Province Key Laboratory of Molecular Tumour Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, ChinaDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Pathology & Guangdong Province Key Laboratory of Molecular Tumour Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, ChinaDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Pathology & Guangdong Province Key Laboratory of Molecular Tumour Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, ChinaDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Pathology & Guangdong Province Key Laboratory of Molecular Tumour Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, ChinaDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Pathology & Guangdong Province Key Laboratory of Molecular Tumour Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China; Corresponding authors at: Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Department of Pathology & Guangdong Province Key Laboratory of Molecular Tumour Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China; Corresponding authors at: Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs have been successfully applied in the treatment of different cancers, the low effectiveness rate has dramatically restrained the clinical application of ICI treatment. N6-methyladenosine (m6A) modification is the most common RNA methylation. Recent studies have pointed out that m6A epigenetic modification could improve the efficacy of ICI blockade treatment. Here, we briefly summarize the relevant mechanisms of tumour immunity, the clinical application of ICIs, the resistance to ICI treatment in cancers, and the m6A epigenetic modification and how it regulates the response to ICI treatment. We attempted to provide a potential strategy for cancer therapy by targeting m6A modification combined with ICI blockade treatment.http://www.sciencedirect.com/science/article/pii/S2001037022004202ICBM6A modificationCancer immunotherapym6A regulators |
| spellingShingle | Weiwei Liu Chaoqun Liu Hui Wang Lijun Xu Jueyu Zhou Sihua Li Yu Cheng Rui Zhou Liang Zhao Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy Computational and Structural Biotechnology Journal ICB M6A modification Cancer immunotherapy m6A regulators |
| title | Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy |
| title_full | Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy |
| title_fullStr | Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy |
| title_full_unstemmed | Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy |
| title_short | Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy |
| title_sort | targeting n6 methyladenosine rna modification combined with immune checkpoint inhibitors a new approach for cancer therapy |
| topic | ICB M6A modification Cancer immunotherapy m6A regulators |
| url | http://www.sciencedirect.com/science/article/pii/S2001037022004202 |
| work_keys_str_mv | AT weiweiliu targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT chaoqunliu targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT huiwang targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT lijunxu targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT jueyuzhou targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT sihuali targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT yucheng targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT ruizhou targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy AT liangzhao targetingn6methyladenosinernamodificationcombinedwithimmunecheckpointinhibitorsanewapproachforcancertherapy |